No Data
The Zenitaka Group continues to rise sharply, viewing the upward revision of the Financial Estimates for the fiscal year ending March 2025 and the increase in the year-end consolidated Dividends as positive factors.
The Zenitakagumi <1811.T> continues to surge, temporarily reaching 3,830 yen, up 255 yen. After the market closed last Friday on the 25th, an upward revision of the consolidated earnings forecast for the fiscal year ending March 2025 and an increase in the expected year-end total Dividends were announced, which was viewed as positive news. The earnings forecast for the fiscal year ending March 2025 is expected to have revenue raised from 120.1 billion yen to 120.6 billion yen (a 0.3% decrease from the previous period) and ordinary profit increased from 3.3 billion yen to 5.09 billion yen (a 2.1% increase from the previous period), turning into a profit increase. This is due to an improvement in profitability in construction and civil engineering work.
April 28th [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Hokkan Holdings <5902> 1,699 yen (4/25) Engaged in food cans, PET bottles, and filling business. The profit forecast for the fiscal year ending March 2025 has been revised upward. The estimated operating profit is 4.5 billion yen (up 2.5% from the previous year). This is an upward revision of about 9% from the previous financial estimates, resulting in a projected increase in profit. Revenue is expected to be lower than the previous forecast, but due to cost reductions in factory expenses and Logistics costs, profit has been upwardly revised. The year-end Dividends have been set at 70 yen.
Astellas Pharma and Hokkan Holdings are in the spotlight, while Nitto Denko and Yamazaki Baking seem to be underperforming.
Last weekend on the 25th, in the US Stocks market, the Dow Jones Industrial Average rose by 20.10 points to 40,113.50, the Nasdaq Composite Index increased by 216.90 points to 17,382.94, and the Chicago Nikkei 225 Futures were up by 220 yen compared to the Osaka daytime at 36,000 yen. The exchange rate was 1 dollar = 143.70-80 yen. In today's Tokyo market, Astellas Pharma <4503>, which experienced a significant increase in operating profit for the fiscal year ending March 2025, at 60.8% growth from a previous financial estimate of a 56.9% decline.
Japan Post, upward revision on March 25, ordinary profit 810 billion yen, down from 760 billion yen.
Japan Post <6178> announced a revision of its financial estimates for the fiscal year ending March 2025. The ordinary profit was revised upwards from 760 billion yen to 810 billion yen. While the profit estimates for the five postal banks <7182> and Japan Post Insurance <7181> will be revised upwards in November 2024 due to improved operating conditions and increased Asset Management revenue, the consolidated financial estimates for the full year are uncertain, particularly regarding the impact on future profits and losses from the upcoming postal rate revision at its consolidated subsidiary, Japan Post.
Key points of attention for the PTS on the 25th = Advantest, Anritsu, Shin-Etsu Chemical, Fujitsu, ETC.
▽ Advantest <6857.T>, the consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is 242 billion yen (a 6% increase compared to the previous period). The assumed Exchange Rates are 140 yen to 1 dollar and 155 yen to 1 euro. It is viewed that the impact of tariff measures on business and performance is minimal. ▽ Anritsu <6754.T>, the consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is 15 billion yen (a 24% increase compared to the previous period). Formulated based on the situation before the tariff measures by the USA are implemented. ▽ Shin-Etsu Chemical <4063.T>, the first quarter of the fiscal year ending March 2026 (
The Zenitaka: Notice regarding revisions to earnings forecasts and dividend forecasts